l-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors

Cancer Research

Volumn 69, Issue 5, 2009, Pages 2126-2132

  Detta, Allah ^a   Cruickshank, Garth S ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; 4 BORONOPHENYLALANINE; AMINO ACID TRANSPORTER; AMINO ACID TRANSPORTER 1; CYCLINE; PHENYLALANINE; UNCLASSIFIED DRUG; 4-BORONOPHENYLALANINE; BORON DERIVATIVE; DRUG DERIVATIVE;

ARTICLE; BRAIN TUMOR; CELL COUNT; CELL CYCLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG UPTAKE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; MASS SPECTROMETRY; METASTASIS; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; IMMUNOHISTOCHEMISTRY; METHODOLOGY; PATHOLOGY; PHYSIOLOGY;

BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; PHENYLALANINE; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 62449221992     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2345     Document Type: Article

References (35)

1. Barth RF, Coderre JA, Vincente MGH, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. CUn Cancer Res 2005:11:3987-4002.
2. Elowitz EH, Bergland RM, Coderre JA, et al. Biodis-tribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy. Neurosurg 1998;42:463-469
3. Joensuu. H, Kankaanranta L, Seppala T, et al. Boron neutron capture therapy of brain tumours: clinical trials at the Finnish facUity using boronophenylalanine. J Neurooncol 2003;62:123-134
4. Liberman SJ, Dagrosa A, Jimenez Rebagliata RA, et al. Biodistribution studies of bronophenyalanine-fructose in melanoma and brain tumour patients in. Argentina. Applied Rad Isotopes 2004;61:1095-1100
5. Bergenheim AT, Capala J, Roslin M, Henriksson R. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT: a microdialysis study. J Neuro-oncol 2005;71:287-293
6. Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiât Res 2000;153:173-180
7. Verry F. System L: heteromeric exchangers of large, neutral, amino acids involved in directional transport. Pflugers Arch 2003;445:529-533
8. Wagner CA, Lang F, Broer S. Function and structure of heterodimeric amino acid transporters. Am J Physiol Cell Physiol 2001;281:C1077-93.
9. Campbell WA, Sah DE, Albina JE Colemen WB Thompson NL. TA.1/LAT-1./CD98 light-chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells: loss of response in tumour ceU. J Biol Chem 2000:275:5437-5454,
10. Wolf DA, Wang S, Panzlca MA, Bassily NH, Thompson NL. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schislsoma masoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 1996;56:5012-5022
11. Coderre JA, Glass JD, Fairchild RD, Roy U, Cohen. S, Fand Z. Selective targeting of boronophenylalanine to melanoma in BALB/c mice for neutron capture therapy. Cancer Res 1987;47:6377-6383
12. Ono K Masunaga S-I Kinashi Yet al. Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumours: its relation to quiescent cell population and tumour cure in. neutron capture therapy. Int J Oncol Biol Phys 1996;34:1081-1086
13. Yoshida F, Matsumara A, Shibata Y et al. Cell cycle dependence of boron uptake from two boron com-pounds used for clinical neutron capture therapy. Cancer Lett 2002:187:135-141
14. Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen H. Transport mechanisms of 3-[.123]iodo-a-m, ethyl-i-tyrosine in a human glioma cell line: comparison with [JH] methyl-L-methionine. J Nucl Med 2000;41:1250-5.
15. Kuwert T, Probst-Cousin S, Woesler B, et al. Iodine-123-a-methyl tyrosine in gliomas: correlation with cellular density and proliferative activity. J Nucl Med 1997:38:1551-1555
16. Zuber P, Hamou MF, de Trlbolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 1988:22: 364-368
17. Raghavan R, Steart PV, Weiler RO. CeU prollferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas glioblastoma multiforme: a Ki-67 study. Neuropathol Appl Neurobiol 1990;16:123-133
18. Detta A, Harland J, Hanif I1 Brown SM1 Cruickshank G. Proliferative activity and in vitro replication of HSV1.7.16 in human, metastatic brain tumours. J Gene Med 2003;5:681-689
19. Chandra S Kabalka GW Leroy I DR, Smith DR, Coderre JA. Imaging of fluorine and boron from fluorinated boronophenylalanine in the same ceU at organelle resolution by correlative ion microscopy and confocal scanning microscopy. Clin Cancer Res 2002;8: 2675-2683
20. Ash KO, Komaromy-Hiller G. Analysis of clinical specimens using inductively coupled plasma mass spectrometry. In: Wong SHY, Sunshine I, editors. Handbook of analytical therapeutic drug monitoring and toxicology. Boca Raton (FL): CRC Press: 1997. p. 108-125.
21. Detta A Hitchcock E. The selective viabUity of human foetal, brain cells. Brain. Res.1990 :520:277-283
22. Okamoto Y, Sakata M, Ogura T et al. Expression, and regulation, of 4F2hc and hLAT1 in human trophohlasts. Am J Physiol Cell Physiol 2002;282:C1.96-204.
23. Celis JE, Bravo R, Larson PM, Fey SJ. Cyclin: a nuclear protein whose level correlates directly with the prolif-erative state of normal as well as transformed cells. Leuk Res 1984;8:143-57.
24. Christensen HN, Handlogten ME1 Lam HS Tager HS Zand R. A bicycUc amino acid to improve discriminations among transport systems. Biol Chem.1969 :244: 1510-1520.
25. Papaspyrou M, Feinendegen LE, Muller-Gartner H-W. Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res 1994;54:6311-6314
26. Lin J, Raoof DA, Thomas DG, et al. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 2004;6:74-84.
27. Boado RJ, Li JY, Nagaya M, Zhang C, Partridge WM. Selective expression of the large neutral amino acid transporter at the blood brain, barrier. Proc Natl Acad Sei U S A 1999:96:12079-12084
28. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumours. Int J Cancer 2006; 1.19:484-492
29. Asano S, Kameyama M, Oura A, et al. L-type amino acid transporter-! expressed in human astrocytomas, U343MGa. Biol Pharm BuU 2007;30:415-422
30. 11C]ty-rosine PET. J Nucl Med 1997;38:1369-1374
31. Sasajima T, Miyagawa T, Oku T, Gelovani JG, Finn R, Blasnerg R. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med MoI Imaging 2004;31: 1244-1256
32. Chandra S, Tjarks W, Lorey DR II, Barth RF. Quantitative subcellular imaging of boron compounds in individual mitotic and interphase human glioblasto-ma cells with imaging secondary ion mass spectrome-try. J Microsc 2008;229:92-103.
33. 10B boron neutron capture therapy: enhancement of tumour dose via beam filtration and dose rate, and the effect of these parameters on minimum boron content: a theo-retical evaluation. Int J Radiât Oncol Biol Phys 1.985:11: 831-40
34. Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiât Res 1999:151:1-18.
35. Nawashiro H, Otani N, Uozumi Y, et al. High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol 2005:22: 89-91.